Alladapt Enrolling Participants for Clinical Study of OIT Therapy to Treat Allergies to All Top 9 at Once


Alladapt Immunotherapeutics is a biopharmaceutical company focused on the development of ADP101, a single oral immunotherapy candidate designed to treat allergies to all “Top 9” allergens simultaneously.

Their Harmony Study is currently seeking participants with food allergy to help doctors test ADP101 with the goal of lessening the severity of food-related allergic reactions.

Click to visit sponsor

If you or your child are 4-55 years of age and have been diagnosed with food allergy to at least one of the following foods, you may qualify:

  • peanut
  • tree nuts
  • cow’s milk
  • chicken’s egg
  • fin fish
  • shrimp
  • sesame seed
  • soy
  • wheat

To determine whether you or your child do qualify, click here to visit the Harmony Study website and fill out their questionnaire.

Click to visit sponsor

Alladapt today also announced they have broken ground on a 53,000 square foot manufacturing and warehouse facility strategically located near the company’s contract manufacturing organization in the greater Philadelphia area.

“One of the great strengths of Alladapt is our technical operations team, which has spent years addressing the specialized, novel challenges associated with producing pharmaceutical-grade single-and multi-allergen oral immunotherapeutic agents,” said Mike Holfinger, PhD, Alladapt’s Chief Technical Officer. “With our Harmony Study actively enrolling, it is exciting to build on our technical achievements by initiating scale-up beyond our Phase 1/2-enabling processes.”

Click to visit sponsor

CEO Ashley Dombkowski, PhD added, “Securing this facility reflects our confidence in this program and marks an important step toward achieving full-scale production capacity to support our Phase 3 program and potential future commercial launch. These investments reaffirm our commitment to transforming the food allergy treatment landscape by advancing therapeutic options to broadly address this chronic and potentially life-threatening disease.”

Alladapt Immunotherapeutics Secures $60 Million in Series C Financing for Development of Food Allergy Therapeutics
Print or share this article
Click to visit sponsor
Dave Bloom
Dave Bloom
Dave Bloom is CEO and "Blogger in Chief" of

Find Allergy-Friendly Products